An analysis of data from the 2019 Global Burden of Disease Study revealed wide variations in lung cancer rates seen throughout the world over the past 30 years.
Results of an epidemiological study that spanned 30 years and 204 countries concluded lung cancer remains a major public health issue globally, prompting authors to call for implementation of tailored scientific and effective interventions. Findings were published in BMC Public Health.
In 2020, a total of 1,796,144 lung cancer deaths were reported, accounting for around 18% of all global cancer deaths, researchers explained. In an effort to better classify and understand prevalence, incidence, and years lived with disability (YLDs), investigators assessed data from the Global Burden of Disease Study (GBD) 2019. They also evaluated the spatiotemporal dynamics of the disease by looking at global, regional, and national trends between 1990 and 2019.
The GBD 2019 includes information from all World Health Organization (WHO) member states, in addition to “a comprehensive assessment on 87 risk factors, 369 diseases and injuries from 1990 to 2019 in 204 countries and territories.”
The countries and territories were grouped into 21 GBD regions and the globe into 5 regions based on sociodemographic index (SDI).
Data showed that in 2019, 3,212,307 individuals had lung cancer, marking a 1.32-fold increase from 1990 (1,385,579), with increases also seen in the age-standardized prevalence rate (ASPR) throughout the same time period.
Additional analyses revealed:
Low SDI nations reported the lowest absolute number and ASP of lung cancer prevalence in 2019, while the highest absolute number and ASR were reported in high SDI nations, the authors wrote.
Regional assessments found:
Although Monaco, Greenland, and Canada had the largest ASPR reported, and China, the United States, and Japan reported the greatest prevalent cases in 2019, the number of patients with lung cancer increased in 95.59% of all countries surveyed, with an 8.43-fold increase seen in the United Arab Emirates and a 7.37-fold increase in Qatar.
The lack of decreasing global trends could be due to a myriad of factors, the authors noted, including high consumption of tobacco in developing countries, ramifications of environmental deterioration and ecological destruction leading to more outdoor air pollution, and increased exposure to indoor hazardous conditions elevated from industrialization and urbanization.
“As per WHO estimates, more than 107,000 people die each year from lung cancer, mesothelioma, and asbestosis resulting from exposure to asbestos in the workplace,” researchers explained.
However, advancements in treatment and surgical techniques over the past 30 years have contributed to improved mortality rates.
Sex differences in lung cancer rates are mainly attributed to differences in smoking, occupational hazards, particulate matter pollution and exposure to carcinogens, while men also have higher blood sugar levels than women, resulting in a disproportionate cancer risk in this population.
Disease burden was not assessed in countries lacking organized architecture to register, record, and report diseases, marking a limitation to the study. Data also did not differentiate between the burden of small cell and non–small cell lung cancer.
“Differences in geographic and country-specific population characteristics emphasize the need for targeted strategies to reduce the lung cancer burden,” the authors concluded.
Reference
Chen X, Mo S, Yi B. The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories. BMC Public Health. Published online May 16, 2022. doi:10.1186/s12889-022-13281-y
Considerations for Immunotherapy Duration in NSCLC: Dr Heather Wakelee
September 11th 2024Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Dr Sandip Patel Previews the Highly Anticipated 50th Anniversary of WCLC
September 6th 2024The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer. Sandip Patel, MD, joined for an interview looking forward to the unique features of this year's meeting.
Read More